MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-WB-10-0061918
Alventa Pharma Limited - pharma in Kolkata, West Bengal, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹142.72 Cr
▲ 82% YoY
Net profit · FY 2025
₹2.04 Cr
Net margin 1.4%
EBITDA · FY 2025
₹5.42 Cr
EBITDA margin 3.8%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹35.05 Lakh
Issued & subscribed
Open charges
₹30 Cr
Secured borrowings
Company age
10 yrs
Est. 2016
Directors on board
3
As per MCA filings
About Alventa Pharma Limited
Data last updated:
Alventa Pharma Limited is a public limited company based in Kolkata, West Bengal, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 October 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN U24299WB2016PLC225674. Its GSTIN is 03AAECE6019L1ZQ (Punjab). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹35.05 Lakh. It was formerly known as Elder Labs Private Limited. It is led by directors including Rubi Mukhopadhyay and Biswajit Pan.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Kolkata, West Bengal.
As per the financials filed for FY 2025, the company reported a revenue of ₹142.72 Cr, a growth of 82% compared to the previous year. For the same year it recorded a net profit of ₹2.04 Cr (net margin 1.4%) and EBITDA of ₹5.42 Cr (EBITDA margin 3.8%). Revenue has grown at a compounded annual rate (CAGR) of 10% over three years and 45% over five years.
The company is associated with 1 brand: Alventa Pharma. As per MCA filings, the company has open charges of ₹30 Cr on record. Court records list 18 cases involving the company, including 3 filed by the company and 14 filed against it; 11 cases are pending.
Alventa Pharma Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-WB-10-0061918). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alventapharma.com.
Company Details of Alventa Pharma Limited
CIN U24299WB2016PLC225674
Registration Number 225674
Incorporation Date 28 October 2016
ROC Kolkata
Listing Status Unlisted
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-WB-10-0061918
CIN History of Alventa Pharma Limited
Alventa Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24299WB2016PLC225674, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24299WB2016PLC225674 | Current |
| U24299UP2016PTC087395 | Previous |
| U24299WB2016PTC225674 | Previous |
Key People
Anand Kumar Parmanandka Additional Director Rubi Mukhopadhyay Director Biswajit Pan Director Recognitions & Rankings of Alventa Pharma
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressRoom No.79 & 80 3rd Floor, At 55 Biplabi Rash Behari Basu Road (Mehta Building), Kolkata, West Bengal, India – 700001
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Alventa Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Alventa Pharma Limited
Alventa Pharma operates one associated brand: Alventa Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops and manufactures generic drugs, offers CDMO services, and exports pharmaceuticals globally. | alventapharma.com |
Business Activity of Alventa Pharma Limited
The main business activity of Alventa Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Alventa Pharma Limited FY 2025 filings available
Alventa Pharma Limited reported revenue of ₹142.72 Cr (up 82% YoY) for FY 2025.
Revenue · FY 2025
₹142.72 Cr ▲ 82%
Net profit · FY 2025
₹2.04 Cr margin 1.4%
EBITDA · FY 2025
₹5.42 Cr margin 3.8%
Compounded Annual Growth Rate (CAGR) of Alventa Pharma Limited
Revenue CAGR growth
1 year
▲ 82%
3 years · compounded
▲ 10%
5 years · compounded
▲ 45%
EBITDA CAGR growth
1 year
▲ 61%
3 years · compounded
▲ 35%
5 years · compounded
▲ 120%
Revenue has grown at a compounded annual rate (CAGR) of 45% over five years, including 82% growth in the latest year. EBITDA rose 61% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Alventa Pharma Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹5.42 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹2.04 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Alventa Pharma Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Alventa Pharma are in the company report.
Premium access
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Alventa Pharma Limited
Alventa Pharma has 3 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anand Kumar Parmanandka Also directs: Aleris Pharmaceuticals Limited, Elder Laboratories Limited, Nicholas Pharma India Limited and 3 more | Additional Director | 29 Apr 2018 | 8 Years 5 Months | Current |
| Rubi Mukhopadhyay Also directs: Smith Stanistreet Pharmaceuticals LLP, Aleris Pharmaceuticals Limited, Elder Laboratories Limited and 2 more | Director | 04 Jun 2018 | 8 Years 4 Months | Current |
| Biswajit Pan Also directs: Aleris Pharmaceuticals Limited, Elder Laboratories Limited, Nicholas Pharma India Limited and 4 more | Director | 07 Jun 2019 | 7 Years 4 Months | Current |
Peer Comparison of Alventa Pharma Limited
Alventa Pharma Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pulse Pharmaceuticals Private Limited | ₹145.08 Cr (FY 2024) | •••• | •••• | -1.0% | •••• | Hyderabad, Telangana, India |
| HBC Lifesciences Private Limited | ₹144.64 Cr (FY 2024) | •••• | •••• | 17.0% | •••• | Gandhinagar, Gujarat, India |
| Goodway Chemicals Private Limited | ₹144.1 Cr (FY 2025) | •••• | •••• | -12.0% | •••• | Mumbai, Maharashtra, India |
| Afrinext Overseas Private Limited | ₹144.02 Cr (FY 2025) | •••• | •••• | 65.0% | •••• | Vadodara, Gujarat, India |
| Immacule Lifesciences Private Limited | ₹143.18 Cr (FY 2025) | •••• | •••• | 34.0% | •••• | Nalagarh, Himachal Pradesh, India |
| Alventa Pharma Limited this company | ₹142.72 Cr (FY 2025) | •••• | •••• | 82.0% | •••• | Kolkata, West Bengal, India |
| Apotex Pharmachem India Private Limited | ₹142.14 Cr (FY 2024) | •••• | •••• | -19.0% | •••• | Bangalore, Karnataka, India |
| Sovereign Pharma Private Limited | ₹142.09 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Mumbai, Maharashtra, India |
| Svizera Labs Private Limited | ₹142.05 Cr (FY 2022) | •••• | •••• | 7.0% | •••• | Thane, Maharashtra, India |
| Ratnatris Pharmaceuticals Private Limited | ₹141.71 Cr (FY 2025) | •••• | •••• | 35.0% | •••• | Ahmedabad, Gujarat, India |
| Lyka Labs Limited Listed | ₹140.73 Cr (FY 2025) | •••• | •••• | 25.0% | •••• | Ankleshwar, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Alventa Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Alventa Pharma Limited
Alventa Pharma Limited is audited by H P JHUNJHUNWALA & COMPANY for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| H P JHUNJHUNWALA & COMPANY | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Alventa Pharma Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Alventa Pharma Limited
Open charges
₹30 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Nov 2025 | Others | ₹20 Cr | Open |
| 22 Dec 2023 | Indian Bank | ₹10 Cr | Open |
Total charge records: 2 View all charges
Legal Cases of Alventa Pharma Limited
Alventa Pharma Limited has 18 court cases on record: 3 filed by Alventa Pharma, 14 filed against it, 1 where it is another party. 11 cases are pending and 7 are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Total cases
18
Filed by the company
3
Filed against the company
14
Pending
11
Disposed
7
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 7 | 5 |
| District courts | 8 | 7 | 6 |
Cases on record (5 of 18)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Thiruvananthapuram, Kerala | Criminal miscellaneous application | Filed against the company by an individual | Pending |
| District court, TUMAKURU, Karnataka | Criminal miscellaneous application | Filed against the company by State at the Instant of Assistant Drug Controller | Pending |
| District court, BENGALURU, Karnataka | Criminal miscellaneous application | Filed against the company by an individual | Pending |
| District court, Panchkula, Haryana | Execution petition | Company is another party | Pending |
| District court, Bhadradri Kothagudem, Telangana | Criminal complaint | Filed against the company by an individual | Pending |
Premium access
Full case history
All 18 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Alventa Pharma Limited
Employment history and EPFO contributions of people linked to Alventa Pharma.
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Alventa Pharma Limited
Alventa Pharma Limited has 9 board changes on record since 2018: 4 appointments and 5 cessations. The latest: Ardhendu Kumar De was appointed as Nominee Director on 03 Aug 2023.
Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101189989 was registered on 04 Nov 2025.
AGM
Alventa Pharma Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Filing
Alventa Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Kolkata.
Charges
A charge with Indian Bank amounted to Rs. 10.00 Cr with Charge ID 100833805 was registered on 22 Dec 2023.
Appointed
Ardhendu Kumar De was appointed as Nominee Director.
Ceased
Natasha Balasaria ceased to be Director.
Appointed
Biswajit Pan was appointed as Director.
Ceased
Jeet Narain Singh ceased to be Director.
Ceased
Phool Chandra Yadav ceased to be Director.
Ceased
Aarti Sharma ceased to be Director.
Appointed
Rubi Mukhopadhyay was appointed as Director.
Ceased
Ramdeo Ram ceased to be Director.
2 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Alventa Pharma Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Alventa Pharma Limited
Premium access
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Alventa Pharma Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Alventa Pharma Limited
Alventa Pharma has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AAECE6019L1ZQ | Punjab | Active | 01 Feb 2019 |
| 02AAECE6019L1ZS | Himachal Pradesh | Active | 12 Dec 2019 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Alventa Pharma Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Alventa Pharma Limited
Frequently Asked Questions about Alventa Pharma Limited
Alventa Pharma is an active public limited company based in Kolkata, West Bengal, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 October 2016 (10+ years old) and is registered under CIN U24299WB2016PLC225674.
Alventa Pharma reported revenue of ₹142.72 Cr for FY 2025 (up 82% YoY).
Alventa Pharma has 3 current directors:
- Anand Kumar Parmanandka - Additional Director
- Rubi Mukhopadhyay - Director
- Biswajit Pan - Director
Alventa Pharma reported a net profit of ₹2.04 Cr (net margin 1.4%) and EBITDA of ₹5.42 Cr (EBITDA margin 3.8%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Alventa Pharma is 10% over three years and 45% over five years. In the latest year (FY 2025) revenue rose 82%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Alventa Pharma is 03AAECE6019L1ZQ, registered in Punjab. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 02AAECE6019L1ZS (Himachal Pradesh).
The CIN (Corporate Identification Number) of Alventa Pharma is U24299WB2016PLC225674. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Alventa Pharma has 18 court cases on record: 3 filed by the company and 14 filed against it. 11 are pending. Most are in the high courts.
Alventa Pharma was incorporated on 28 October 2016, making it 10+ years old. It is registered with the Registrar of Companies, Kolkata.
The peers of Alventa Pharma by revenue are Pulse Pharmaceuticals Private Limited, HBC Lifesciences Private Limited, Goodway Chemicals Private Limited, Afrinext Overseas Private Limited, Immacule Lifesciences Private Limited and 5 more, all in the Pharma industry (Formulations).
Ardhendu Kumar De was appointed as Nominee Director on 03 Aug 2023. Natasha Balasaria ceased to be Director on 08 Jun 2019. Biswajit Pan was appointed as Director on 07 Jun 2019. Alventa Pharma has 9 board changes on record in total.